Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | ALPL | P05186 | 1/20 | 0.37 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.37 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.37 |
| ▸ | KCNQ4 | P56696 | 1/20 | 0.37 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.37 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30313140 | 1.00 | CYP3A4 (0.50) | CYP3A4ALDH1A1HPGDTDP1L3MBTL1 | |
| SCHEMBL5070735 | 0.87 | CYP3A4 (0.63) | CYP3A4ALDH1A1HPGDTDP1L3MBTL1 | |
| SCHEMBL1339760 | 0.86 | L3MBTL1 (0.58) | CYP3A4ALDH1A1HPGDTDP1L3MBTL1 | |
| SCHEMBL57580 | 0.85 | ALDH1A1 (0.51) | CYP3A4ALDH1A1HPGDTDP1MEN1 | |
| SCHEMBL6118430 | 0.84 | L3MBTL1 (0.44) | CYP3A4L3MBTL1RAB9AMEN1ALOX15 | |
| SCHEMBL20052481 | 0.81 | L3MBTL1 (0.44) | CYP3A4L3MBTL1RAB9AMEN1ALOX15 | |
| SCHEMBL3880131 | 0.78 | CYP3A4 (0.54) | CYP3A4ALDH1A1HPGDTDP1MEN1 | |
| SCHEMBL13556581 | 0.78 | CYP3A4 (0.58) | CYP3A4ALDH1A1HPGDTDP1MEN1 | |
| SCHEMBL20052480 | 0.78 | L3MBTL1 (0.44) | CYP3A4ALDH1A1HPGDL3MBTL1RAB9A | |
| SCHEMBL5891689 | 0.78 | CYP3A4 (0.73) | CYP3A4ALDH1A1HPGDTDP1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 207 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116874436-A | Preparation method of letromycin intermediate | 济宁学院 | 2023-10-13 | — | — | CN | claimed |
| CN-115386245-A | Preparation method and application of lipophilic carbon nitride nanosheet | 浙江理工大学 | 2022-11-25 | — | — | CN | claimed |
| CN-116874436-B | Leitemivir Process for the preparation of intermediates | 济宁学院 | 2025-08-08 | — | — | CN | disclosed |
| CN-119798172-A | Preparation method of Leitemivir key intermediate dihydroquinazoline ester | 仁合益康集团有限公司 | 2025-04-11 | — | — | CN | disclosed |
| US-20240408093-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. | 2024-12-12 | — | — | US | disclosed |
| US-RE49897-E1 | Salts of a dihydroquinazoline derivative | AIC246 AG & CO. KG (DE) | 2024-04-02 | — | — | US | disclosed |
| EP-4328218-A2 | PHARMACEUTICAL PREPARATION COMPRISING AN ANTIVIRAL DIHYDROQUINAZOLINE DERIVATIVE | AIC246 AG & Co. KG (DE) | 2024-02-28 | — | — | EP | disclosed |
| EP-3556350-B1 | PHARMACEUTICAL PREPARATION COMPRISING AN ANTIVIRAL DIHYDROQUINAZOLINE DERIVATIVE WITH S CONFIGURATION IN POSITION 4 | AIC246 AG & CO KG (DE) | 2024-01-10 | — | — | EP | disclosed |
| US-RE49698-E1 | Substituted dihydroquinazolines | AIC246 AG & CO. KG (DE) | 2023-10-17 | — | — | US | disclosed |
| US-RE49698-E1 | Substituted dihydroquinazolines | AIC246 AG & CO. KG (DE) | 2023-10-17 | — | — | US | disclosed |
| CN-116874436-A | Preparation method of letromycin intermediate | 济宁学院 | 2023-10-13 | — | — | CN | disclosed |
| US-20010011135-A1 | Omega-carboxyaryl subsituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC | 2001-08-02 | — | — | US | disclosed |
| US-20010011136-A1 | omega-carboxyyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC | 2001-08-02 | — | — | US | disclosed |
| CN-1283180-A | Inhibition of raf kinase using symmerical and unsymmerical substituted diphenyl ureas | BAYER AG (US) | 2001-02-07 | — | — | CN | disclosed |
| EP-1049664-A1 | INHIBITION OF RAF KINASE USING SYMMETRICAL AND UNSYMMETRICAL SUBSTITUTED DIPHENYL UREAS | Bayer Corporation (US) | 2000-11-08 | — | — | EP | disclosed |
| EP-1042305-A1 | INHIBITION OF p38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS | Bayer Corporation (US) | 2000-10-11 | — | — | EP | disclosed |
| WO-2000041698-A1 | φ-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS | BAYER CORPORATION (US) | 2000-07-20 | — | — | WO | disclosed |
| WO-2000042012-A1 | φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BAYER CORPORATION (US) | 2000-07-20 | — | — | WO | disclosed |
| WO-1999032436-A1 | INHIBITION OF RAF KINASE USING SYMMETRICAL AND UNSYMMETRICAL SUBSTITUTED DIPHENYL UREAS | BAYER CORPORATION (US) | 1999-07-01 | — | — | WO | disclosed |
| WO-1999032463-A1 | INHIBITION OF p38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS | BAYER CORPORATION (US) | 1999-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010011135-A1 | Omega-carboxyaryl subsituted diphenyl ureas as raf kinase inhibitors | BRAF, RAF1, ARAF | CYP3A4 2209/4885ALDH1A1 1431/4885HPGD 2652/4885 |
| US-20010011136-A1 | omega-carboxyyaryl substituted diphenyl ureas as raf kinase inhibitors | BRAF, ARAF, RAF1 | CYP3A4 3500/4885ALDH1A1 1887/4885HPGD 2749/4885 |
| US-20240408093-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE | FGFR3, FGFR1, ERBB3 | CYP3A4 2811/4885ALDH1A1 4423/4885HPGD 4233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.